title: In vitro antiproliferative and antiangiogenic effects of Flavin7.
abstract: Flavin7 (F7) is a nutritional supplement often taken by cancer patients in Central Europe during chemo- and radiation therapy. In this study, investigation of the antiproliferative and antiangiogenic activities of this supplement were performed. Flavin7 showed antiproliferative activity in Jurkat as well as in HeLa cells. It significantly reduced the growth of both cancer cell lines at the doses of 200 microg/ml to 20 microg/ml (p<0.001 and p<0.01, respectively). In F7-treated Jurkat cells we found a significant increase in the fraction of cells with sub-G(0)/G(1) DNA content, which is considered to be a marker of apoptotic cell death. Apoptosis was also confirmed by annexin V staining and DNA fragmentation. Furthermore, F7 at the doses of 100 microg/ml to 4 microg/ml inhibited endothelial cell migration and capillary tube formation what indicates its potential antiangiogenic properties. Flavin7 also inhibited the activity of matrix metalloproteinases (MMPs), preferentially MMP-9, at the doses of 100 microg/ml to 4 microg/ml. Our data suggest that F7 possesses marked antiproliferative and antiangiogenic properties in vitro. Further research is needed to elucidate also its in vivo activities.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, P.J. Safarik University, Kosice, Slovak Republic. jan.mojzis@upjs.sk
authors.forename: J
authors.initials: J
authors.lastname: Mojzis
authors.forename: M
authors.initials: M
authors.lastname: Sarisský
authors.forename: M
authors.initials: M
authors.lastname: Pilátová
authors.forename: V
authors.initials: V
authors.lastname: Voharová
authors.forename: L
authors.initials: L
authors.lastname: Varinská
authors.forename: G
authors.initials: G
authors.lastname: Mojzisová
authors.forename: A
authors.initials: A
authors.lastname: Ostro
authors.forename: P
authors.initials: P
authors.lastname: Urdzík
authors.forename: R
authors.initials: R
authors.lastname: Dankovcik
authors.forename: L
authors.initials: L
authors.lastname: Mirossay
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D053938:DNA Fragmentation; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D042783:Endothelial Cells / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D005415:Flavins / Q000494:pharmacology*; D005419:Flavonoids / Q000494:pharmacology*; D006367:HeLa Cells; D006801:Humans; D019169:Jurkat Cells; D061965:Matrix Metalloproteinase Inhibitors; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D011480:Protease Inhibitors / Q000494:pharmacology; D013267:Stilbenes / Q000494:pharmacology*
chemical_list: D020533:Angiogenesis Inhibitors; D000972:Antineoplastic Agents, Phytogenic; C531446:Flavin7; D005415:Flavins; D005419:Flavonoids; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D013267:Stilbenes